Relief Therapeutics Holding (XSWX:RLF) Other Current Assets: CHF0.30 Mil (As of Jun. 2025)


XSWX:RLF Relief Therapeutics Holding SA XSWX:RLF
20 GF Score
Price CHF3.00
GF Value CHF6.28
! 5 Warning Signs
View Full Analysis

What is Relief Therapeutics Holding Other Current Assets?

Relief Therapeutics Holding XSWX:RLF +4.90% 20 Other Current Assets is CHF0.30 Mil as of Jun. 2025. GuruFocus rates XSWX:RLF with a GF Score™ of 20/100 and a GF Value™ of CHF6.28. The stock has 5 warning signs investors should review.

Relief Therapeutics Holding's other current assets for the quarter that ended in Jun. 2025 was CHF0.30 Mil.

Relief Therapeutics Holding's quarterly other current assets increased from Jun. 2024 (CHF0.71 Mil) to Dec. 2024 (CHF1.54 Mil) but then declined from Dec. 2024 (CHF1.54 Mil) to Jun. 2025 (CHF0.30Mil).

Relief Therapeutics Holding's annual other current assets declined from Dec. 2022 (CHF0.86 Mil) to Dec. 2023 (CHF0.34 Mil) increased from Dec. 2023 (CHF0.34 Mil) to Dec. 2024 (CHF1.54 Mil).


Relief Therapeutics Holding Other Current Assets Related Terms


Relief Therapeutics Holding Other Current Assets Historical Data

* Premium members only.

The historical data trend for Relief Therapeutics Holding's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Relief Therapeutics Holding Other Current Assets Chart

Relief Therapeutics Holding Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.54 7.07 0.86 0.34 1.54

Relief Therapeutics Holding Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.05 0.34 0.71 1.54 0.30
XSWX:RLF
20GF Score
Relief Therapeutics Holding SA XSWX:RLF
Other Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Relief Therapeutics Holding Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

Frequently Asked Questions Learn more about Other Current Assets →
What does a Other Current Assets of CHF0.30 Mil mean?
Relief Therapeutics Holding (XSWX:RLF) has a Other Current Assets of CHF0.30 Mil as of Jun. 2025. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Relief Therapeutics Holding.
Is Relief Therapeutics Holding's Other Current Assets too high?
Relief Therapeutics Holding's current Other Current Assets is CHF0.30 Mil. Overall, Relief Therapeutics Holding has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Relief Therapeutics Holding's Other Current Assets compare to KTTA and OSRH?
Relief Therapeutics Holding's Other Current Assets of CHF0.30 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Assets for a Biotechnology company?
A good Other Current Assets depends on the Biotechnology industry context. However, Other Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Assets mean?
A high Other Current Assets can signal that a stock is expensive relative to its fundamentals. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Relief Therapeutics Holding. Relief Therapeutics Holding's current Other Current Assets is CHF0.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Relief Therapeutics Holding stock overvalued right now?
Relief Therapeutics Holding (XSWX:RLF) has a current Other Current Assets of CHF0.30 Mil. The stock's GF Value™ is CHF6.28, compared to a current price of CHF3.00 — trading 52.2% below its estimated fair value. The current Other Current Assets is CHF0.30 Mil. Relief Therapeutics Holding's overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Assets calculated?
Other Current Assets is calculated from a company's financial statements. For Relief Therapeutics Holding (XSWX:RLF), the current Other Current Assets is CHF0.30 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Relief Therapeutics Holding (XSWX:RLF) Overvalued in 2026?

Based on GuruFocus' analysis, Relief Therapeutics Holding stock appears to be undervalued. The current stock price of CHF3.00 is trading 52.2% below its estimated GF Value™ of CHF6.28.

Key valuation signals for XSWX:RLF:

  • Other Current Assets: CHF0.30 Mil
  • GF Value™: CHF6.28 vs. price of CHF3.00 (52.2% below fair value)
  • GF Score™: 20/100 with 5 warning signs

No single metric tells the full story. See the XSWX:RLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Relief Therapeutics Holding Business Description

Address Avenue de Secheron 15, Geneva, CHE, 1202
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products, and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development, such as RLF-TD011 and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast, among others. Geographically, the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.
20GF Score

Get the complete analysis for XSWX:RLF

Other Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF3.00
Price
CHF6.28
GF Value